Literature DB >> 11277028

[Therapy with preferential and specific COX-2 inhibitors].

D O Stichtenoth1, J C Frölich.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11277028     DOI: 10.1007/s001080050769

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


× No keyword cloud information.
  4 in total

Review 1.  Current approaches to prevent NSAID-induced gastropathy--COX selectivity and beyond.

Authors:  Jan C Becker; Wolfram Domschke; Thorsten Pohle
Journal:  Br J Clin Pharmacol       Date:  2004-12       Impact factor: 4.335

Review 2.  The second generation of COX-2 inhibitors: what advantages do the newest offer?

Authors:  Dirk O Stichtenoth; Jürgen C Frölich
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 3.  [Pharmacological treatment of osteoarthritis in the elderly].

Authors:  T Brabant; D Stichtenoth
Journal:  Z Rheumatol       Date:  2005-10       Impact factor: 1.372

4.  Prostanoid Receptor Subtypes and Its Endogenous Ligands with Processing Enzymes within Various Types of Inflammatory Joint Diseases.

Authors:  Mohammed A Al-Madol; Mohammed Shaqura; Thilo John; Rudolf Likar; Reham Said Ebied; Magdi M Salih; Sascha Treskatsch; Michael Schäfer; Shaaban A Mousa
Journal:  Mediators Inflamm       Date:  2020-11-12       Impact factor: 4.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.